Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL

$172,190K08FY2024CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Lisa Madalen Niswandercontact

View original record on NIH RePORTER →

Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL · GrantIndex